Results 111 to 120 of about 8,893 (235)

Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review

Frontiers in Clinical Diabetes and Healthcare
Traditionally, Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), a pivotal class of drug, mimics the actions of endogenous Glucagon-like peptide-1, which have been found to be remarkable in the treatment of type 2 diabetes alongside other ...
Bisma Fatima Hammad, Nimrah Zafar, Muneeb Ullah, Syeda Jazilah Faisal, Fizzah Iftikhar, Haadia Waheed, Muhammad Waleed Muzaffar, Khadija Ahmed, Faz Ashraf, Komal Zahid, Maimoona Akhtar, Mohammed Mahmmoud Fadelallah Eljack   +11 more
doaj   +1 more source

Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE‐Based Network Meta‐Analysis

Obesity, Volume 34, Issue 2, Page 279-293, February 2026.
ABSTRACT Objective This review compared antiobesity strategies—obesity management medications (OMM), endoscopic bariatric procedures (EBP), and metabolic bariatric surgery (MBS)—with lifestyle intervention, placebo, or no therapy (LSI/Pbo/NT). Methods This network meta‐analysis included randomized clinical trials comparing OMM, EBP, and MBS versus LSI ...
Maurizio De Luca, Ricardo V. Cohen, Amanda Belluzzi, Giuseppe Navarra, Nicola Di Lorenzo, Tarissa B. Z. Petry, Paolo Sbraccia, Luca Busetto, Silvio Buscemi, Rocco Barazzoni, Benedetta Ragghianti, Edoardo Mannucci, Matteo Monami   +12 more
wiley   +1 more source

Semaglutide versus caloric restriction‐induced weight loss: insights into effects on skeletal muscle mass and function

The Journal of Physiology, EarlyView.
Harsh Shah, Julio E. Ayala
wiley   +1 more source

Metabolic Outcomes in Patients With Type 2 Diabetes Prescribed Incretin‐Based Therapy and Referred or Not to a Weight Management Clinic: A Single‐Center Retrospective Analyses

Obesity Science &Practice, Volume 12, Issue 1, February 2026.
ABSTRACT Background Incretin therapies yield strong metabolic improvements, but whether adding a weight‐management (WM) clinic confers additional benefit beyond pharmacotherapy alone in routine care is unclear. Objective Evaluate whether referral to WM clinic, alongside standard diabetes care, provides additional benefit for adults with type 2 diabetes
Kathleen M. Robinson, Stephanie H. Rodriguez, Cyril Pedagarla, Patrick Ten Eyck, Marcelo Correia, Ayotunde Dokun   +5 more
wiley   +1 more source

Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 803-816, February 2026.
Abstract Treatment with GLP‐1 receptor agonists (GLP‐1 RAs) is effective in reducing body weight in individuals with overweight and type 2 diabetes (T2D). However, measurements indicate that a considerable portion of the weight loss derives from fat‐free mass (FFM), including skeletal muscle, which may compromise metabolic health and physical function.
Viktor Aimelet, Jens Juul Holst
wiley   +1 more source

A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity

Journal of Obesity
Obesity is considered the leading public health problem in the medical sector. The phenotype includes overweight conditions that lead to several other comorbidities that drastically decrease health.
Ibrahim Abdullah bin Ahmed
doaj   +1 more source

THE POTENTIAL OF GLP-1 IN THE TREATMENT OF AUTOIMMUNE DISEASES: A REVIEW OF MECHANISMS AND CLINICAL DATA [PDF]

Introduction: Autoimmune diseases are a heterogeneous group of disorders characterized by dysregulated immune responses against self-antigens, leading to chronic inflammation and progressive organ damage.
Agata Andrzejczyk, Aleksandra Tomaszewska, Angelika Lewandowska, Gabriela Szpila, Joanna Gadzinowska, Krzysztof Feret, Maciej Kokoszka, Małgorzata Stopyra, Michalina Chodór, Natalia Nafalska   +9 more
core   +2 more sources

SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease

Cardiovascular Diabetology
Background Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to reduce cardiovascular risk and mortality in patients with type 2 diabetes mellitus (T2D), yet remain underutilized ...
Ziad Arow, Tzipi Hornik-Lurie, Ranin Hilu, Ela Giladi, Yoav Arnson, Hana Vaknin-Assa, Abid Assali, David Pereg, For the CARDIAB research group   +8 more
doaj   +1 more source

The Role of GLP-1 Receptor Agonists in Eating Disorders: Appetite Regulation and Neurobiological Mechanisms

Neurologijos seminarai
Valgymo sutrikimai, tokie kaip nervinė anoreksija, nervinė bulimija ir persivalgymo sutrikimas, dažnai siejami su neurobiologinėmis disfunkcijomis, įskaitant dopamino ir atlygio sistemų pokyčius.
Julija Blažytė, Robertas Strumila
doaj   +1 more source

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP‐1R agonist survodutide in mice

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2437-2442, March 2026.
Fen Long, Tenagne D. Challa, Vissarion Efthymiou, Manuel Klug, Thomas Klein, Heike Neubauer, Christian Wolfrum, Carla Horvath   +7 more
wiley   +1 more source